November 15, 2018
A federal judge has denied three pharmaceutical companies' move to quash subpoenas for information on their plans to make generic substitutes of Allergan’s drug Restasis in multidistrict litigation over its alleged efforts to delay the generic versions’ launch, saying in-house counsel can view the data without compromising confidentiality.
November 14, 2018
Health benefits providers that refunded members for the cost of Allergan's dry-eye medication Restasis will be able to move forward on the majority of the state law claims the drugmaker wanted thrown out, a New York federal judge overseeing multidistrict antitrust litigation has ruled.
October 18, 2018
A New York federal judge has ordered Allergan to produce documents from the files its CEO and other senior executives on a deal that transferred patents to a Native American tribe for plaintiffs in multidistrict litigation accusing the drugmaker of illegally delaying a generic version of its dry-eye medication Restasis.